ZA978573B - Medical treatment - Google Patents

Medical treatment

Info

Publication number
ZA978573B
ZA978573B ZA978573A ZA978573A ZA978573B ZA 978573 B ZA978573 B ZA 978573B ZA 978573 A ZA978573 A ZA 978573A ZA 978573 A ZA978573 A ZA 978573A ZA 978573 B ZA978573 B ZA 978573B
Authority
ZA
South Africa
Prior art keywords
pct
sec
date
humans
medical treatment
Prior art date
Application number
ZA978573A
Other languages
English (en)
Inventor
Peter Finian Kelly
Stephen Paul Jones
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of ZA978573B publication Critical patent/ZA978573B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
ZA978573A 1996-09-25 1997-09-25 Medical treatment ZA978573B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9619962.5A GB9619962D0 (en) 1996-09-25 1996-09-25 Medical treatment

Publications (1)

Publication Number Publication Date
ZA978573B true ZA978573B (en) 1999-03-25

Family

ID=10800448

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA978573A ZA978573B (en) 1996-09-25 1997-09-25 Medical treatment

Country Status (26)

Country Link
US (1) US6162831A (de)
EP (1) EP1007023B1 (de)
JP (1) JP2001501608A (de)
KR (1) KR20000048568A (de)
CN (1) CN1231604A (de)
AT (1) ATE239460T1 (de)
AU (1) AU722129B2 (de)
BG (1) BG103278A (de)
BR (1) BR9711414A (de)
CA (1) CA2266438A1 (de)
DE (1) DE69721838T2 (de)
DK (1) DK1007023T3 (de)
ES (1) ES2199374T3 (de)
GB (1) GB9619962D0 (de)
HR (1) HRP970519A2 (de)
HU (1) HUP9904545A3 (de)
IL (1) IL128851A (de)
NO (1) NO991425L (de)
NZ (1) NZ334668A (de)
PL (1) PL332423A1 (de)
PT (1) PT1007023E (de)
SK (1) SK32199A3 (de)
TR (1) TR199900649T2 (de)
TW (1) TW415842B (de)
WO (1) WO1998013033A1 (de)
ZA (1) ZA978573B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
PL365463A1 (en) * 1999-03-19 2005-01-10 Knoll Gmbh Treatment of osteoarthritis
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US11103542B2 (en) 2002-03-13 2021-08-31 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
US9655932B2 (en) * 2002-03-13 2017-05-23 Kibow Biotech, Inc. Composition and method for preventing or treating gout or hyperuricemia
NZ538966A (en) * 2002-10-05 2006-11-30 Hanmi Pharm Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
WO2006012438A2 (en) * 2004-07-21 2006-02-02 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of insulin resistance
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
KR20080046601A (ko) * 2006-11-22 2008-05-27 에스케이케미칼주식회사 보관안정성이 우수한 시부트라민 함유 포접복합체
US11179426B2 (en) 2016-12-29 2021-11-23 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
US20210369769A1 (en) * 2018-11-02 2021-12-02 Dyve Biosciences, Inc. Management of risk of cation overload and electrolyte imbalance with topically applied buffers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
CA2138998A1 (en) * 1992-06-23 1994-01-06 James W. Young Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine
CA2139000A1 (en) * 1992-06-23 1994-01-06 James W. Young Methods and compositions for treating depression and other disorders using optically pure(+) sibutramine
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment

Also Published As

Publication number Publication date
WO1998013033A1 (en) 1998-04-02
NO991425D0 (no) 1999-03-24
AU722129B2 (en) 2000-07-20
NZ334668A (en) 2000-07-28
EP1007023B1 (de) 2003-05-07
CN1231604A (zh) 1999-10-13
IL128851A (en) 2001-08-26
EP1007023A1 (de) 2000-06-14
PL332423A1 (en) 1999-09-13
DE69721838T2 (de) 2004-01-22
BR9711414A (pt) 2000-04-25
TR199900649T2 (xx) 1999-07-21
SK32199A3 (en) 1999-12-10
NO991425L (no) 1999-03-24
CA2266438A1 (en) 1998-04-02
BG103278A (en) 2000-01-31
PT1007023E (pt) 2003-08-29
ES2199374T3 (es) 2004-02-16
IL128851A0 (en) 2000-01-31
HUP9904545A3 (en) 2000-12-28
KR20000048568A (ko) 2000-07-25
AU4385197A (en) 1998-04-17
TW415842B (en) 2000-12-21
GB9619962D0 (en) 1996-11-13
HRP970519A2 (en) 1998-08-31
HUP9904545A2 (hu) 2000-11-28
ATE239460T1 (de) 2003-05-15
DK1007023T3 (da) 2003-08-25
JP2001501608A (ja) 2001-02-06
US6162831A (en) 2000-12-19
DE69721838D1 (de) 2003-06-12

Similar Documents

Publication Publication Date Title
GB9619962D0 (en) Medical treatment
PH31220A (en) Medical treatment.
LU90956I2 (fr) Metvix principe actif méthylaminolevulinique sous forme d'un selde préférence l'hyhrochlorure méthylaminolevulinique
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
TR200102646T2 (tr) Yeme bozukluklarının tedavi edilmesi.
WO2000056315A8 (en) Treatment of pain
MXPA01009464A (es) Metodo para el tratamiento de apnea de sueno.
MXPA01009467A (es) Metodo para controlar el aumento de peso asociado con farmacos terapeuticos.
BG105999A (en) Treatment of osteoarthritis
BG106000A (en) Treatment of hiatial hernia
RU99108729A (ru) Способ лечения
MXPA01009462A (es) Tratamiento de calculos biliares.
RU2001126350A (ru) Применение фторированных триазолов для лечения боли и аффективных нарушений и нарушений внимания
TH18470A (th) อนุพันธ์เมลาโทนินสำหรับใช้ในการรักษาความผิดปกติของการหลับ
MXPA01009465A (es) Perdida de peso despues del embarazo.